Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Aptose Biosciences Inc chart...

About the Company

aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt

CEO

William Rice

Exchange

NASDAQ

Website

https://aptose.com/

$0M

Total Revenue

54

Employees

$11M

Market Capitalization

-0.30

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $APTO News

NeuroBo Phase 2a study for MASH drug to proceed as planned

on MSN ago, source:

NeuroBo (NRBO) said a safety review committee has recommended that a Phase 2a study of its drug candidate DA-1241 for the treatment of MASH continue without any modifications.

Which Is a Better Investment, Apellis Pharmaceuticals Inc or Avidity Biosciences Inc Stock?

6d ago, source: American Association of Individual Investors

Learn more about whether Apellis Pharmaceuticals Inc or Avidity Biosciences Inc is a better investment based on AAII's A+ ...

EQB: Stocks Undervalued by Analyst Consensus on TSX (EQB)

21y ago, source: The Globe and Mail

EQB Inc is among the group of undervalued stocks on the Toronto Stock Exchange. This means the consensus value for each stock on this list is above its current price. This report is generated monthly.

Avidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surge

12d ago, source:

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on RNA stock, giving a Buy rating on March 4. Joseph Schwartz has ...

Morguard: Stocks Undervalued by Analyst Consensus on TSX (MRC)

17d ago, source:

Morguard Corp is among the group of undervalued stocks on the Toronto Stock Exchange. This means the consensus value for each stock on this list is above its current price.

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates

5d ago, source: Hosted on MSN

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago. These ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...